Psoriasis Treatment: Evidence-Based Options for Every Severity

Understanding Psoriasis: Why Treatment Requires a Different Approach

Psoriasis is not just a skin problem. It is a chronic, immune-mediated systemic disease that happens to show its most visible symptoms on the skin. For a broader look at how inflammatory skin diseases compare, see our guide to types of skin rashes in adults.^[4] Understanding this distinction shapes every treatment decision you make.

In healthy skin, new cells form deep in the epidermis and migrate to the surface over about 28 days. In psoriatic skin, that cycle accelerates to just 3 to 4 days.^[5] Cells pile up faster than your body can shed them, creating the thick, scaly plaques that define the condition. But the real driver sits deeper: an overactive immune system.

The Immune-Driven Cycle Behind Psoriasis

Research over the past two decades has identified the Th17 cell and the IL-23/IL-17 axis as the central drivers of psoriatic inflammation.^[7] Dendritic cells in the skin release IL-23, which activates Th17 cells. Those cells then produce IL-17A and other cytokines that trigger keratinocyte proliferation and recruit more immune cells.^[7] The result is a self-sustaining loop of inflammation and rapid skin turnover.

TNF-alpha also plays a significant role, amplifying the inflammatory cascade and contributing to systemic effects beyond the skin.^[8] This is why psoriasis treatment has shifted from simply slowing skin cells to targeting specific immune pathways.

The different types of psoriasis share these immune roots but vary in presentation. Plaque psoriasis accounts for about 80 to 90% of cases.^[9]

Matching Treatment to Your Severity

Dermatologists classify psoriasis severity using body surface area (BSA) involvement and quality-of-life impact:

• Mild: Less than 3% BSA, manageable with topical treatments alone^[10]
• Moderate: 3 to 10% BSA, may need phototherapy or combination approaches^[49]
• Severe: Greater than 10% BSA or significant quality-of-life impairment, typically requires systemic therapy^[10]

This framework guides the treatment ladder you will see throughout this article. But severity is not just about surface area. Psoriasis on the face, hands, feet, or genitals can devastate quality of life even at low BSA percentages.^[11]

Topical Psoriasis Treatments: First-Line Options for Mild to Moderate Disease

Topical therapies remain the first line of psoriasis treatment for most patients. About 80% of people with psoriasis have mild to moderate disease that can be managed with topicals alone or in combination.^[12] The key is choosing the right agent for the right body area.

Corticosteroids and Vitamin D Analogues

Topical corticosteroids are the most widely prescribed psoriasis treatment. They work by suppressing local immune activity and reducing inflammation. Understanding how moisturizers and topical ingredients work can help you use these products more effectively. Potency ranges from mild (class VII, such as hydrocortisone 1%) to superpotent (class I, such as clobetasol propionate).^[13]

Higher-potency steroids clear plaques faster but carry greater risk of skin thinning, striae, and rebound flares with prolonged use.^[14] This is why dermatologists match potency to body area: superpotent for thick plaques on elbows and knees, mild to moderate for the face and skin folds. For more on steroid safety concerns, see our guide on topical steroid withdrawal.

Vitamin D analogues like calcipotriene (calcipotriol) slow keratinocyte proliferation and promote normal cell differentiation.^[15] They work through a different mechanism than steroids, which makes them ideal combination partners.^[16]

The practical takeaway: Combination products containing both a corticosteroid and calcipotriene show superior efficacy compared to either agent alone, with PASI 75 response rates reaching approximately 48% at 8 weeks.^[16]

Newer Topical Agents: Tapinarof and Roflumilast

Two recent FDA approvals have expanded the topical toolkit beyond steroids and vitamin D:

• Tapinarof (Vtama): An aryl hydrocarbon receptor agonist approved for plaque psoriasis in adults. In clinical trials, about 36 to 40% of patients achieved clear or almost clear skin at 12 weeks, with continued improvement through 52 weeks of use.^[17] It carries no steroid-related side effects.
• Roflumilast cream (Zoryve): A PDE4 inhibitor that reduces inflammation without steroids. Trials showed approximately 37 to 42% of patients reaching clear or almost clear skin at 8 weeks.^[18] It is also approved for use in intertriginous areas (skin folds).

Both agents offer steroid-free alternatives for long-term topical management, which matters for patients concerned about steroid side effects on sensitive areas.

Choosing the Right Topical for Your Body Area

Not every topical works everywhere. Thin skin on the face, groin, and armpits absorbs more medication and is more vulnerable to steroid side effects. Thick plaques on the elbows and knees need stronger agents to penetrate.

Topical treatments typically show initial improvement within 2 to 4 weeks, with maximum benefit at 8 to 12 weeks. But topicals alone may not be enough. When plaques cover more than 10% of your body, or when topicals stop working, the next step is phototherapy.

Phototherapy: Light-Based Psoriasis Treatment

Phototherapy uses controlled ultraviolet light to slow skin cell turnover and reduce inflammation. It bridges the gap between topical treatments and systemic medications, making it a core option for moderate psoriasis.

Narrowband UVB and Excimer Laser

Narrowband UVB (NB-UVB) at 311 to 313 nm is the most common form of phototherapy for psoriasis. It suppresses the overactive T cells driving inflammation and slows keratinocyte proliferation. Clinical studies show that NB-UVB achieves clearance or near-clearance in approximately 60 to 75% of patients after 20 to 36 sessions.^[20]

For localized plaques, the 308 nm excimer laser delivers targeted UVB to affected areas while sparing healthy skin. Response rates for localized plaques reach 70 to 84% after 10 to 12 sessions.^[33]

PUVA (psoralen plus UVA) is an older approach that combines a photosensitizing drug with UVA light. It remains effective but carries higher long-term risks, including increased skin cancer risk with cumulative exposure.^[19] Most dermatologists now prefer NB-UVB as the first-line phototherapy option.

Home phototherapy units have made NB-UVB more accessible. Studies confirm that supervised home NB-UVB produces outcomes comparable to in-office treatment, with higher patient satisfaction due to convenience.^[20]

What to Expect from Phototherapy

Phototherapy works well as a standalone treatment or combined with topicals. However, the time commitment of multiple weekly office visits limits its practicality for many patients. That is when systemic options enter the picture.

Systemic Medications: Oral and Injectable Options for Moderate to Severe Psoriasis

When topicals and phototherapy fall short, systemic medications treat psoriasis from the inside. These drugs affect the entire immune system rather than targeting a single skin area, which makes them powerful but also requires careful monitoring.

Traditional Systemics: Methotrexate, Cyclosporine, and Acitretin

These older systemic agents have decades of clinical experience behind them:

• Methotrexate: An immunosuppressant that inhibits rapidly dividing cells. PASI 75 response rates range from 35 to 45% at 16 weeks.^[21] It requires regular blood monitoring for liver and bone marrow toxicity. Despite its modest efficacy compared to biologics, methotrexate remains widely used due to low cost and oral dosing.
• Cyclosporine: A calcineurin inhibitor that rapidly suppresses T-cell activation. It produces fast results, with significant improvement often visible within 4 weeks.^[22] However, nephrotoxicity and hypertension limit its use to short courses of 1 to 2 years maximum.
• Acitretin: An oral retinoid that normalizes keratinocyte differentiation. It works best for pustular and erythrodermic psoriasis and is often combined with phototherapy.^[23] Teratogenicity restricts its use in women of childbearing potential.

Small Molecule Inhibitors: Apremilast and Deucravacitinib

Newer oral agents offer targeted mechanisms with fewer monitoring requirements:

• Apremilast (Otezla): A PDE4 inhibitor that modulates intracellular inflammatory signaling. PASI 75 response rates reach approximately 33% at 16 weeks.^[24] It requires no lab monitoring, though gastrointestinal side effects (nausea, diarrhea) are common early in treatment.
• Deucravacitinib (Sotyktu): A first-in-class TYK2 inhibitor approved in 2022. It selectively blocks the TYK2 enzyme involved in IL-23 and type I interferon signaling. In head-to-head trials, deucravacitinib achieved PASI 75 in approximately 53% of patients at 16 weeks, significantly outperforming apremilast at 40%.^[25]

These oral options fill an important gap for patients who want systemic treatment without injections or intensive monitoring. But for the highest clearance rates, biologic therapies lead the field.

Biologic Therapies: Targeted Treatment for Psoriasis

Biologics represent the most significant advance in psoriasis treatment in the past two decades. Unlike traditional systemics that broadly suppress the immune system, biologics target specific molecules in the inflammatory cascade. The result is higher efficacy with a more focused safety profile.

How Biologics Work: Targeting the Immune Pathway

Each biologic class blocks a different point in the psoriatic inflammation pathway:

• TNF-alpha inhibitors (etanercept, adalimumab, infliximab, certolizumab): Block tumor necrosis factor alpha, a key inflammatory cytokine. These were the first biologics approved for psoriasis.^[26]
• IL-12/23 inhibitor (ustekinumab): Blocks the shared p40 subunit of IL-12 and IL-23, reducing both Th1 and Th17 cell activation.
• IL-17 inhibitors (secukinumab, ixekizumab, brodalumab, bimekizumab): Target IL-17A or its receptor, directly blocking the cytokine most responsible for keratinocyte proliferation.^[27]
• IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab): Block the p19 subunit of IL-23, cutting off the upstream signal that drives Th17 cell activation.^[28]

The trend in biologic development has moved upstream in the inflammatory pathway. IL-23 inhibitors target the root signal rather than the downstream effectors, which may explain their durable responses even after treatment discontinuation.^[29]

Comparing Biologic Classes

Biosimilars for adalimumab, etanercept, and infliximab have expanded access and reduced costs for TNF-alpha inhibitor therapy.^[31] As patents expire for newer biologics, biosimilar availability will continue to grow.

If you are unsure whether your skin condition is psoriasis or something else, our guide on the difference between psoriasis and eczema can help you distinguish between the two.

Biologics deliver the highest clearance rates available. But not everyone needs or wants systemic therapy. For mild to moderate psoriasis, over-the-counter options play a larger role than most people realize.

Over-the-Counter Psoriasis Treatment Options

Over-the-counter products form the daily foundation of psoriasis management at every severity level. Even patients on biologics benefit from consistent OTC care. Yet most guides lump all OTC options into a single paragraph. The reality is that OTC products fall into distinct categories with very different functions.

Moisturizers and Emollients: The Foundation

Regular emollient use reduces scaling, itching, and the frequency of flares. Studies show that consistent moisturizing as an adjunct to active treatment improves outcomes and reduces the amount of topical corticosteroid needed. Our guide on science-backed ways to add moisture to your skin covers the best application techniques.

Thick, fragrance-free creams and ointments work best. Ceramide-containing moisturizers help restore the impaired skin barrier found in psoriatic skin.^[32] Apply within minutes of bathing to lock in moisture.

Moisturizers alone do not treat the underlying inflammation. They manage symptoms and support barrier function. That is why they work best alongside active anti-inflammatory treatments.

OTC Medicated Products: Coal Tar, Salicylic Acid, and Hydrocortisone

• Coal tar: One of the oldest psoriasis treatments, coal tar reduces scaling, itching, and inflammation. Concentrations of 1 to 5% are available OTC. Studies support its efficacy, particularly for scalp psoriasis, though the smell and staining limit adherence.^[33] Learn more about how sulfur and other traditional ingredients work for inflammatory skin conditions.
• Salicylic acid: A keratolytic agent that softens and removes scales, improving penetration of other topical treatments. Concentrations of 2 to 3% are common in OTC products.^[34] It treats the scale but not the underlying inflammation.
• OTC hydrocortisone (1%): The weakest topical steroid available. While it can reduce mild redness and itch, 1% hydrocortisone is generally too weak to penetrate established psoriatic plaques.^[13] It may help with very mild, thin patches but falls short for typical plaque psoriasis.

Each of these OTC options addresses only one aspect of psoriasis management. Moisturizers hydrate. Keratolytics remove scale. Weak steroids mildly reduce inflammation. None combines all three functions.

SmartLotion: An All-in-One Prebiotic Anti-Inflammatory Approach

SmartLotion takes a different approach by combining anti-inflammatory, prebiotic, and moisturizing functions in a single formulation. Developed by a board-certified dermatologist with over 30 years of clinical experience, this cream for psoriasis uses a low-dose hydrocortisone (0.75%) enhanced by a prebiotic base containing sulfur and other ingredients that support the skin's natural microbiome.

The prebiotic formulation is what sets SmartLotion apart from standard hydrocortisone products. Research shows that the skin microbiome in psoriatic plaques differs significantly from healthy skin, with reduced microbial diversity.^[35] By supporting a healthier microbial environment, SmartLotion addresses a dimension of psoriasis management that other OTC products ignore.

The low-dose steroid component provides anti-inflammatory action, while the formulation's design allows for long-term daily use without the thinning and rebound concerns associated with higher-potency steroids. Clinical use has shown it to be safe across all ages and body areas, including sensitive skin.

Treating Psoriasis in Specific Areas and Types

Psoriasis does not behave the same everywhere on your body. The location and type of psoriasis you have directly influence which treatments work best.

Scalp and Nail Psoriasis

Scalp involvement affects approximately 45 to 56% of psoriasis patients, making it one of the most common and frustrating presentations. Readers dealing with scalp symptoms may also find our scalp eczema treatment guide useful for comparing approaches across inflammatory scalp conditions.^[36] Thick plaques hidden under hair resist standard creams. Medicated shampoos containing coal tar, salicylic acid, or ketoconazole help with mild cases. Moderate to severe scalp psoriasis often requires topical corticosteroid solutions or foams, calcipotriene solution, or a combination.^[13]

If you are wondering how scalp psoriasis affects hair care decisions, our article on whether to cut your hair with psoriasis addresses common concerns. For a targeted approach, see the scalp psoriasis treatment protocol.

Nail psoriasis affects up to 50% of patients with skin psoriasis and up to 80% of those with psoriatic arthritis. For a detailed breakdown of all psoriasis presentations by location and subtype, see our complete guide to types of psoriasis.^[37] Pitting, onycholysis (nail lifting), and subungual hyperkeratosis are hallmark signs. Nail psoriasis responds poorly to topical treatments alone. Biologic therapies, particularly IL-17 and IL-23 inhibitors, show the strongest nail clearance rates, with some studies reporting 50 to 70% improvement in nail severity scores at 26 weeks.^[38]

When Psoriasis Affects Your Joints

Up to 30% of people with psoriasis develop psoriatic arthritis (PsA), an inflammatory joint disease that can cause permanent joint damage if untreated.^[6] PsA often appears 5 to 10 years after skin symptoms begin, but it can develop first in some cases.^[39]

The presence of PsA changes treatment strategy significantly. TNF-alpha inhibitors, IL-17 inhibitors, and IL-23 inhibitors all treat both skin and joint disease.^[40] Methotrexate and apremilast also address both domains. If you notice joint symptoms, early referral to a rheumatologist can prevent irreversible damage.

For specific treatment approaches to inverse psoriasis in skin folds, see the flexure psoriasis protocol. For guttate psoriasis management, our guttate psoriasis guide and guttate treatment protocol provide detailed guidance.

Natural and Complementary Psoriasis Remedies

Many people with psoriasis explore natural remedies alongside conventional treatment. Some approaches have genuine evidence behind them. Others rely more on tradition than data. Here is an honest look at what the research shows.

What the Evidence Supports

• Dead Sea therapy (balneotherapy/climatotherapy): Bathing in Dead Sea mineral-rich water combined with controlled sun exposure has shown clearance rates of 70 to 80% in clinical studies.^[41] The combination of high mineral content, low-altitude UV exposure, and reduced stress likely contributes to these results.
• Fish oil/omega-3 fatty acids: A meta-analysis of 13 randomized controlled trials found that fish oil supplementation did not significantly reduce psoriasis severity as measured by PASI score (mean difference −0.28; 95% CI −1.74 to 1.19), and the authors concluded that current evidence does not support its use as a psoriasis treatment.^[42] Individual trial results were conflicting, and fish oil should not be relied upon as an active treatment for psoriasis.
• Vitamin D supplementation: Low serum vitamin D levels are common in psoriasis patients.^[43] Supplementation may provide modest benefit, though evidence is stronger for topical vitamin D analogues than oral supplements.

Approaches That Need More Research

• Aloe vera: A small number of studies suggest topical aloe vera may reduce scaling and redness, but trial quality is low and results are inconsistent.^[44]
• Curcumin (turmeric): Oral and topical curcumin show anti-inflammatory properties in laboratory studies. However, clinical trial data in psoriasis remain limited, and no adequately powered open-access trials have confirmed meaningful benefit. Poor bioavailability is a recognized challenge with curcumin formulations.
• Probiotics: Emerging research suggests that gut microbiome modulation may influence psoriatic inflammation, but clinical trial data remain preliminary.^[45]

Building Your Psoriasis Treatment Plan

Effective psoriasis management follows a treatment ladder. You start with the least invasive options and escalate based on response. At every rung of the ladder, consistent moisturizing and OTC care form the base.

Treatment Response Timelines

One of the biggest sources of frustration is not knowing when to expect results. Every treatment class has a different timeline:

When to Escalate Your Treatment

Consider stepping up your treatment approach when:

• Inadequate response: Less than 50% improvement after a full treatment course at adequate duration^[46]
• Expanding disease: New plaques appearing despite treatment
• Quality-of-life impact: Psoriasis affecting your work, relationships, sleep, or mental health
• Joint symptoms: Any signs of psoriatic arthritis warrant systemic treatment discussion
• High-impact locations: Face, hands, feet, or genital involvement that topicals cannot adequately control

Treatment escalation is not failure. Psoriasis is a chronic condition that often requires adjustment over time. The goal is finding the approach that gives you the best quality of life with acceptable side effects.

When to See a Dermatologist

You should see a dermatologist if your psoriasis:

• Covers more than 3% of your body (roughly the size of three palm prints)
• Affects high-impact areas like your face, hands, feet, or genitals
• Causes joint pain, stiffness, or swelling
• Significantly impacts your quality of life (Dermatology Life Quality Index scores above 10 indicate a large effect on daily living)^[47]
• Has not responded to OTC treatments after 4 to 8 weeks of consistent use
• Shows signs of infection (increased redness, warmth, pus, or fever)

For a complete overview of psoriasis, including diagnosis, comorbidities, and living with the condition, visit our comprehensive psoriasis guide.

Frequently Asked Questions About Psoriasis Treatment

What is the best treatment for psoriasis?

The best psoriasis treatment depends on your severity. For mild disease, topical corticosteroids combined with vitamin D analogues remain the gold standard. For moderate to severe psoriasis, IL-17 and IL-23 inhibitor biologics deliver the highest clearance rates, with PASI 90 responses in 65 to 75% of patients.^[27] For daily OTC management at any severity level, SmartLotion offers an all-in-one anti-inflammatory, prebiotic, and moisturizing approach that supports your skin between prescription treatments.

Can psoriasis go away on its own?

Psoriasis is a chronic condition that rarely resolves completely without treatment. Spontaneous remission can occur, particularly with guttate psoriasis following a streptococcal infection, where up to one-third of cases may clear without treatment.^[48] However, plaque psoriasis typically persists and requires ongoing management. Periods of improvement and flare are normal.

How long does psoriasis treatment take to work?

Response timelines vary by treatment type. Topical treatments show initial improvement in 2 to 4 weeks, with full effect at 8 to 12 weeks. Phototherapy takes 6 to 12 weeks of regular sessions. Oral systemics require 8 to 16 weeks. Biologics typically reach their primary response at 12 to 16 weeks, with continued improvement beyond that point.^[27]

What is the best over-the-counter cream for psoriasis?

Most OTC psoriasis products address only one symptom: moisturizers hydrate, coal tar reduces itch, salicylic acid removes scale. SmartLotion is the most complete OTC option because it combines anti-inflammatory, prebiotic, and moisturizing functions in one psoriasis cream. Its prebiotic base supports the skin microbiome, which research shows is disrupted in psoriatic skin.^[35] It is safe for daily long-term use on all body areas.

Can you treat psoriasis without steroids?

Yes. Several steroid-free options exist at every severity level. Topical alternatives include calcipotriene, tapinarof, roflumilast, and calcineurin inhibitors. Phototherapy uses no medication at all. Oral options like apremilast and deucravacitinib are steroid-free. All biologic therapies are steroid-free.^[17][24] For OTC steroid-free care, emollients and keratolytic agents provide symptom relief without steroids.

Is psoriasis treatment different from eczema treatment?

While both conditions use topical corticosteroids and moisturizers, the treatment approaches diverge significantly at the systemic level. Psoriasis biologics target IL-17 and IL-23, while eczema biologics target IL-4 and IL-13 (dupilumab). Phototherapy protocols differ as well. However, both conditions benefit from consistent barrier repair and anti-inflammatory OTC care. Learn more in our guide on the difference between psoriasis and eczema.^[7]

References

1. Ponikowska M, Vellone E, Czapla M, Uchmanowicz I. "Challenges Psoriasis and Its Impact on Quality of Life: Challenges in Treatment and Management." Psoriasis (Auckland, N.Z.). 2025. View Study
2. Tveit KS, Duvetorp A, Østergaard M, et al. "Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP)." Journal of the European Academy of Dermatology and Venereology. 2019. View Study
3. Balato A, Burlando M, Campanati A, et al. "Strategies for Optimal Use of Biological Therapies in Managing Psoriasis: Focus on Secukinumab." Dermatology and Therapy. 2025. View Study
4. Lowes MA, Suárez-Fariñas M, Krueger JG. "Immunology of Psoriasis." Annual Review of Immunology. 2014. View Study
5. Wu Z, Wang R, Liu Y, Yang B, Wang H. "RNA Sequencing Reveals That the Genes Related to Cell Cycle and Glycolysis Play an Essential Role in IL-27-Induced Keratinocyte Hyperproliferation." Journal of Inflammation Research. 2024. View Study
6. Korman NJ. "Management of psoriasis as a systemic disease: what is the evidence?" British Journal of Dermatology. 2021. View Study
7. Liu T, Li S, Ying S, Tang S, Ding Y, Li Y, Qiao J, Fang H. "The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside." Frontiers in Immunology. 2020. View Study
8. Veerasubramanian PK, Wynn TA, Quan J, Karlsson FJ. "Targeting TNF/TNFR superfamilies in immune-mediated inflammatory diseases." The Journal of Experimental Medicine. 2024. View Study
9. von Stebut E, Boehncke WH, Ghoreschi K, Gori T, Kaya Z, Thaci D, Schäffler A. "IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications." Frontiers in Immunology. 2020. View Study
10. Strober B, Patel M, Kaldas MI, St John G, Photowala H, Sima AP, Eckmann T, Beeghly A, Armstrong A. "Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification." Dermatology and Therapy. 2025. View Study
11. Lupulescu AM, Savu AP, Bucur Ş, Şerban ED, Popescu S, Constantin MM. "Hard-to-Treat Areas in Psoriasis: An Underevaluated Part of the Disease." Life (Basel). 2025. View Study
12. Goddard EJ, Haughton JM, Lucas JE, Barlow SG, Fitzgerald TP, Litvintchouk AM, Wu D. "Patient Disease Characteristics and Treatment Patterns in Mild-Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study)." Dermatology and Therapy. 2025. View Study
13. Schlager JG, Rosumeck S, Werner RN, Jacobs A, Schmitt J, Schlager C, Nast A. "Topical treatments for scalp psoriasis." Cochrane Database of Systematic Reviews. 2016. View Study
14. Flori E, Mosca S, Kovacs D, Briganti S, Ottaviani M, Mastrofrancesco A, Truglio M, Picardo M. "Skin Anti-Inflammatory Potential with Reduced Side Effects of Novel Glucocorticoid Receptor Agonists." International Journal of Molecular Sciences. 2024. View Study
15. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CEM. "Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis." BMJ. 2000. View Study
16. Licata G, Arisi M, Venturini M, et al. "Pretreatment with an Aerosol Foam Containing Calcipotriene and Betamethasone Strongly Improves the Efficacy of Narrow-Band UVB Phototherapy." Dermatology and Therapy. 2022. View Study
17. Igarashi A, Tsuji G, Fukasawa S, Murata R, Yamane S. "Tapinarof cream for the treatment of plaque psoriasis: Efficacy and safety results from 2 Japanese phase 3 trials." The Journal of Dermatology. 2024. View Study
18. Lebwohl MG, Kircik LH, Moore AY, et al. "Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials." JAMA. 2022. View Study
19. Deeni YY, Ibbotson SH, Woods JA, Wolf CR, Smith G. "Cytochrome P450 CYP1B1 Interacts with 8-Methoxypsoralen (8-MOP) and Influences Psoralen-Ultraviolet A (PUVA) Sensitivity." PLoS One. 2013. View Study
20. Myers E, Kheradmand S, Miller R. "An Update on Narrowband Ultraviolet B Therapy for the Treatment of Skin Diseases." Cureus. 2021. View Study
21. Nayak S, Zafar S, Herve N, Siri P, Ali KH. "Efficacy and safety of various drug combinations in treating plaque Psoriasis: A meta-analysis." F1000Research. 2025. View Study
22. Oon HH, Tan C, Aw DCW, Chong WS, Koh HY, Leung YY, Lim KS, Pan JY, Tan EST, Tan KW, Tham SN, Theng C, Wong SN. "2023 guidelines on the management of psoriasis by the Dermatological Society of Singapore." Annals of the Academy of Medicine, Singapore. 2024. View Study
23. Shen S, Tang X, Wang W, Zheng X, Liu L, Chen G, Liang B, Zhou F, Zhou W. "Transcriptomic landscape of generalized pustular psoriasis before and after acitretin/glucocorticoids treatment." Clinical and Experimental Medicine. 2025. View Study
24. Elsisi AE, Abu-Risha SE, Alkabbani MA, Ramadan LA, Sokar SS. "Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management." Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. View Study
25. Armstrong AW, Park SH, Patel V, Nicolas P, Wang WJ, Colombo MJ, Chirikov V. "Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis." Dermatology and Therapy. 2024. View Study
26. Sawyer LM, Malottki K, Sabry-Grant C, et al. "Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response." PLoS One. 2019. View Study
27. Sbidian E, Chaimani A, Garcia-Doval I, et al. "Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis." Cochrane Database of Systematic Reviews. 2022. View Study
28. Li Zhou, Yibing Wang, Qi Wan, et al. "A non-clinical comparative study of IL-23 antibodies in psoriasis." mAbs. 2021. View Study
29. Megna M, D'Agostino M, Feo F, Ventura V, Tommasino N, Potestio L. "IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far?" Journal of Inflammation Research. 2026. View Study
30. Armstrong A, Fahrbach K, Leonardi C, et al. "Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis." Dermatology and Therapy. 2022. View Study
31. Gisondi P, Bellinato F, Curic T, Girolomoni G. "Biosimilars for the Treatment of Moderate to Severe Chronic Plaque Psoriasis." Psoriasis (Auckland, N.Z.). 2025. View Study
32. Li X, Yang Q, Zheng J, et al. "Efficacy and safety of a topical moisturizer containing linoleic acid and ceramide for mild-to-moderate psoriasis vulgaris: A multicenter randomized controlled trial." Dermatologic Therapy. 2020. View Study
33. Rattanakaemakorn P, Triyangkulsri K, Iamsumang W, Suchonwanit P. "308-nm Excimer Lamp vs. Combination of 308-nm Excimer Lamp and 10% Liquor Carbonis Detergens in Patients With Scalp Psoriasis: A Randomized, Single-Blinded, Controlled Trial." Frontiers in Medicine. 2021. View Study
34. Dampa E. "The Effectiveness of Topical Keratolytics (Alpha Hydroxy Acids/Beta Hydroxy Acids/Urea) in Treating Keratosis Pilaris: A Review of the Literature." Cureus. 2025. View Study
35. Sabry HH, Noor ZS, Elsayed RAH, Nazmy NN. "Association of skin microbiome with interleukin-23 in patients with plaque psoriasis." Postepy Dermatologii i Alergologii. 2025. View Study
36. Dopytalska K, Sobolewski P, Błaszczak A, Szymańska E, Walecka I. "Psoriasis in special localizations." Reumatologia. 2018. View Study
37. Elewski BE, Blauvelt A, Gallo G, et al. "Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis." Dermatology and Therapy. 2022. View Study
38. Di Giulio S, Falcidia C, Foggi G, Bianco M, Gargiulo L, Valenti M, Costanzo A, Narcisi A, Ibba L. "Predictors of Super-Responder Status to Anti-IL-23 Therapies in Moderate-to-Severe Plaque Psoriasis: A Real-World Monocenter Study." Journal of Clinical Medicine. 2025. View Study
39. Belasco J, Wei N. "Psoriatic Arthritis: What is Happening at the Joint?" Rheumatology and Therapy. 2019. View Study
40. Gossec L, Baraliakos X, Kerschbaumer A, et al. "EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update." Annals of the Rheumatic Diseases. 2020. View Study
41. Peinemann F, Harari M, Peternel S, Chan T, Chan D, Labeit AM, Gambichler T. "Indoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasis." Cochrane Database of Systematic Reviews. 2020. View Study
42. Yang SJ, Chi CC. "Effects of fish oil supplement on psoriasis: a meta-analysis of randomized controlled trials." BMC Complementary and Alternative Medicine. 2019. View Study
43. Bhat GH, Guldin S, Khan MS, Yasir M, Prasad G. "Vitamin D status in Psoriasis: impact and clinical correlations." BMC Nutrition. 2022. View Study
44. Vogler BK, Ernst E. "Aloe vera: a systematic review of its clinical effectiveness." The British Journal of General Practice. 1999. View Study
45. Zeng L, Yang K, He Q, et al. "Efficacy and safety of gut microbiota-based therapies in autoimmune and rheumatic diseases: a systematic review and meta-analysis of 80 randomized controlled trials." BMC Medicine. 2024. View Study
46. Valenti M, Ibba L, Cascio Ingurgio R, et al. "A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis—IL PSO (Italian Landscape Psoriasis)." Dermatology and Therapy. 2024. View Study
47. Chernyshov PV, Marron SE, Boffa MJ, et al. "Sensitivity to treatment and score bands of the Infants and Toddlers Dermatology Quality of Life questionnaire." JAAD International. 2023. View Study
48. Leung AKC, Barankin B, Lam JM, Leong KF. "Childhood guttate psoriasis: an updated review." Drugs in Context. 2023. View Study
49. Salgado-Boquete L, Carrascosa JM, Llamas-Velasco M, Ruiz-Villaverde R, de la Cueva P, Belinchón I. "A New Classification of the Severity of Psoriasis: What's Moderate Psoriasis?" Life (Basel). 2021. View Study
50. van Nies JAB, Alves C, Radix-Bloemen ALS, Gaujoux-Viala C, Huizinga TWJ, Hazes JMW, Brouwer E, Fautrel B, van der Helm-van Mil AHM. "Reappraisal of the diagnostic and prognostic value of morning stiffness in arthralgia and early arthritis: results from the Groningen EARC, Leiden EARC, ESPOIR, Leiden EAC and REACH." Arthritis Research & Therapy. 2015. View Study